Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
05
2020
revised:
18
06
2020
accepted:
21
10
2020
pubmed:
8
11
2020
medline:
16
2
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
Primary sclerosing cholangitis (PSC) is associated with progressive liver disease and cholangiocarcinoma. Although risk stratification is crucial for making clinical decisions, it is hindered by a scarcity of proven prognostic markers. To assess the value of novel anti-glycoprotein 2 (anti-GP2) and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA) in combination with PSC-specific clinical and laboratory markers as predictors of quality of life, disease severity, and cholangiocarcinoma in two large, independent cohorts of PSC patients METHODS: Discovery (338 Polish patients) and validation (178 German patients) cohorts with PSC were evaluated. Anti-GP2 (isoforms 1/4) was detected by ELISAs and PR3-ANCA by chemiluminescence immunoassay. Clinical and laboratory data were collected and analysed. The outcome was defined as liver transplantation-free survival and occurrence of cholangiocarcinoma during follow-up. In the discovery group, anti-GP2 Anti-GP2 and PR3-ANCA are prognostic antibodies in PSC as they identify patients at risk of severe disease, poor survival and biliary cancer.
Sections du résumé
BACKGROUND
Primary sclerosing cholangitis (PSC) is associated with progressive liver disease and cholangiocarcinoma. Although risk stratification is crucial for making clinical decisions, it is hindered by a scarcity of proven prognostic markers.
AIMS
To assess the value of novel anti-glycoprotein 2 (anti-GP2) and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA) in combination with PSC-specific clinical and laboratory markers as predictors of quality of life, disease severity, and cholangiocarcinoma in two large, independent cohorts of PSC patients METHODS: Discovery (338 Polish patients) and validation (178 German patients) cohorts with PSC were evaluated. Anti-GP2 (isoforms 1/4) was detected by ELISAs and PR3-ANCA by chemiluminescence immunoassay. Clinical and laboratory data were collected and analysed. The outcome was defined as liver transplantation-free survival and occurrence of cholangiocarcinoma during follow-up.
RESULTS
In the discovery group, anti-GP2
CONCLUSIONS
Anti-GP2 and PR3-ANCA are prognostic antibodies in PSC as they identify patients at risk of severe disease, poor survival and biliary cancer.
Identifiants
pubmed: 33159471
doi: 10.1111/apt.16153
pmc: PMC7821312
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Immunoglobulin A
0
Serine
452VLY9402
Serine Proteases
EC 3.4.-
Myeloblastin
EC 3.4.21.76
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
302-313Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1051-8
pubmed: 22653260
Clin Chim Acta. 2015 Mar 10;442:82-3
pubmed: 25625482
Gut. 2017 Jan;66(1):137-144
pubmed: 27406039
Front Immunol. 2018 Aug 28;9:1959
pubmed: 30233574
J Clin Invest. 2001 Nov;108(10):1417-22
pubmed: 11714731
Scand J Gastroenterol. 2002 Oct;37(10):1205-11
pubmed: 12408527
Hepatology. 2020 Jan;71(1):214-224
pubmed: 29742811
Scand J Gastroenterol Suppl. 1987;139:41-52
pubmed: 3324299
Hepatology. 2011 Nov;54(5):1842-52
pubmed: 21793028
Inflamm Bowel Dis. 2015 Dec;21(12):2864-72
pubmed: 26273818
J Hepatol. 2017 Dec;67(6):1298-1323
pubmed: 28802875
Liver Int. 2015 Jun;35(6):1764-71
pubmed: 25388280
Clin Chem Lab Med. 2014 Apr;52(4):483-94
pubmed: 24231127
PLoS One. 2014 Nov 14;9(11):e112877
pubmed: 25397578
Clin Chim Acta. 2013 Sep 23;424:267-73
pubmed: 23806819
Mayo Clin Proc. 2000 Jul;75(7):688-94
pubmed: 10907383
Biochim Biophys Acta. 2000 Apr 25;1491(1-3):376-80
pubmed: 10760606
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2152-65
pubmed: 26051390
Gut. 2018 Oct;67(10):1864-1869
pubmed: 28739581
Adv Clin Chem. 2016;77:77-101
pubmed: 27717419
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
Viszeralmedizin. 2015 Jun;31(3):156-61
pubmed: 26468308
Scand J Gastroenterol. 2020 Jul;55(7):806-813
pubmed: 32568566
Sci Rep. 2018 Jan 10;8(1):399
pubmed: 29321484
Lancet. 2018 Jun 23;391(10139):2547-2559
pubmed: 29452711
J Hepatol. 2000 May;32(5):734-41
pubmed: 10845659
Inflamm Bowel Dis. 2017 Sep;23(9):1624-1636
pubmed: 28691939
Hepatology. 2016 Feb;63(2):644-59
pubmed: 26290473
Front Biosci (Landmark Ed). 2012 Jan 01;17:959-69
pubmed: 22201783
J Crohns Colitis. 2013 Aug;7(7):e273-4
pubmed: 23337370
PLoS One. 2018 Dec 17;13(12):e0208974
pubmed: 30557305
Aliment Pharmacol Ther. 2021 Jan;53(2):302-313
pubmed: 33159471
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
Gut. 2005 Nov;54(11):1622-9
pubmed: 15961522
Clin Chim Acta. 2012 Apr 11;413(7-8):719-26
pubmed: 22265712
J Hepatol. 2002 Mar;36(3):321-7
pubmed: 11867174
Liver Int. 2015 Sep;35(9):2194-201
pubmed: 25546575
Dig Dis Sci. 2016 Jun;61(6):1692-9
pubmed: 26743764
Clin Rev Allergy Immunol. 2013 Aug;45(1):109-16
pubmed: 23345025
J Hepatol. 2000 Feb;32(2):182-7
pubmed: 10707856
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Gut. 2020 Apr;69(4):665-672
pubmed: 31243055
PLoS One. 2017 Apr 20;12(4):e0176264
pubmed: 28426778
J Crohns Colitis. 2015 Aug;9(8):659-68
pubmed: 25968583
Gastroenterology. 2016 Oct;151(4):660-669.e4
pubmed: 27342213
Am J Clin Pathol. 1999 Apr;111(4):507-13
pubmed: 10191771
Auto Immun Highlights. 2020 Mar 16;11(1):6
pubmed: 32178720
Gastroenterology. 2010 Mar;138(3):1102-11
pubmed: 19944697
Clin Chim Acta. 2011 Apr 11;412(9-10):718-24
pubmed: 21195704
Inflamm Bowel Dis. 2016 Nov;22(11):2648-2657
pubmed: 27753692
Gastroenterology. 1991 May;100(5 Pt 1):1385-91
pubmed: 2013383